Close

AvidBiotics receives SBIR grant to develop protein antibacterial technology

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

Smart Sensors in Biomanufacturing Transform Fluid Monitoring

Smart Sensors & Monitoring in Fluid Systems in Biomanufacturing Precision...

Revolutionary Drug Delivery System With Nanoparticle Tech

When Willus Fisher, a doctorate candidate at the University...

Revolutionizing Biologics : Inhalation And Liquid Delivery

It is noteworthy that the pharmaceutical industry is gradually...

AvidBiotics has received new Small Business Innovation Research (SBIR) grant from the National Institute of Allergic and Infectious Diseases of the National Institutes of Health to further develop targetable bactericidal proteins to kill Clostridium difficile bacteria.

As part of the grant, AvidBiotics will receive $600,000 funds spreading over two years.

AvidBiotics chief executive officer David Martin said Clostridium difficile has become the most frequent cause of hospital-acquired infections overtaking methicillin-resistant Staph. Aureus.

“This new funding will help support our preclinical research and advance Avidocinâ„¢ proteins towards the clinic,” Martin added.

AvidBiotics’ Avidocin antibacterial proteins will kill target organisms without collateral damage to non-targeted bacteria in bacterial health threats.

 

Latest stories